Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas · 2026
Read Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study by Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13462094.txt.
Description
Yoann Zelmat and colleagues compare, in a 2026 French study, the risk of an irregular heartbeat side effect across a family of cancer drugs called Bruton's tyrosine kinase inhibitors. These drugs treat B-cell blood cancers. The oldest, ibrutinib, is known to trigger atrial fibrillation, a fast, uneven heartbeat. Whether newer class drugs carry the same risk was unclear. Records came from the health insurance database for 2015 to 2024.
The study followed 26,393 adults starting one of three class drugs or a comparison drug, venetoclax, excluding anyone with earlier fibrillation. Within one year, hospital-treated fibrillation was most common with ibrutinib, at a little over two percent, and far lower with the newer and comparison drugs. Adjusted models put ibrutinib's risk several times higher than each rival. The two newer drugs did not differ from the comparison drug. The authors advise closer heart monitoring for patients on ibrutinib.
Catalog record
| CREATOR | Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32500 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |